litlas
Log inCreate account

Arata Azuma

Active 1979–2025

80
Papers
22,518
Citations
56
h-index
75
i10-index

Citations

Citations per year for Arata Azuma1981: 2 citations1983: 2 citations1984: 2 citations1985: 3 citations1988: 8 citations1992: 3 citations1993: 2 citations1994: 4 citations1996: 1 citations1997: 2 citations1998: 5 citations1999: 2 citations2000: 5 citations2001: 3 citations2002: 13 citations2003: 13 citations2004: 12 citations2005: 14 citations2006: 20 citations2007: 28 citations2008: 31 citations2009: 31 citations2010: 48 citations2011: 54 citations2012: 59 citations2013: 52 citations2014: 89 citations2015: 164 citations2016: 189 citations2017: 208 citations2018: 221 citations2019: 884 citations2020: 1,135 citations2021: 1,088 citations2022: 860 citations2023: 590 citations2024: 1,030 citations2025: 380 citations2026: 12 citations1982: no citations, so this year is not shown1986–1987: no citations, so these years are not shown1989–1991: no citations, so these years are not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,893 citing papers, 21.1% of this breakdownChina: 779 citing papers, 8.7% of this breakdownJapan: 728 citing papers, 8.1% of this breakdownUnited Kingdom: 714 citing papers, 7.9% of this breakdownItaly: 598 citing papers, 6.7% of this breakdownGermany: 553 citing papers, 6.1% of this breakdownFrance: 441 citing papers, 4.9% of this breakdownCanada: 367 citing papers, 4.1% of this breakdownAustralia: 263 citing papers, 2.9% of this breakdownNetherlands: 263 citing papers, 2.9% of this breakdownSpain: 236 citing papers, 2.6% of this breakdownSwitzerland: 202 citing papers, 2.2% of this breakdown
0%21.1%Other 21.8%

Institutions

Fields

  • Medicine90.4%
  • Biochemistry, Genetics and Molecular Biology5.9%
  • Immunology and Microbiology1.5%
  • Engineering0.5%
  • Computer Science0.4%
  • Health Professions0.2%
  • Other1.1%

Topics

  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis25.4%
  • Systemic Sclerosis and Related Diseases6.7%
  • Sarcoidosis and Beryllium Toxicity Research5.9%
  • Chronic Obstructive Pulmonary Disease (COPD) Research4.4%
  • Pulmonary Hypertension Research and Treatments2.9%
  • Inflammatory Myopathies and Dermatomyositis2.9%
  • Other51.8%

Coauthors

All papers

Open in search
  1. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

    Authors: Luca Richeldi, Roland M. du Bois, Ganesh Raghu, Arata Azuma, Kevin M. Brown, Ulrich Costabel, Vincent Cottin, Kevin R. Flaherty, David M. Hansell, Yoshikazu Inoue, Dong Soon Kim, Martin Kolb, Andrew G. Nicholson, Paul W. Noble, Moisés Selman, Hiroyuki Taniguchi, Michèle Brun, Florence Le Maulf, M Girard, Susanne Stowasser, Rozsa Schlenker‐Herceg, Bernd Disse, Harold R. Collard - New England Journal of Medicine 2014 cited by 4,611

  2. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

    Authors: Ganesh Raghu, Martine Rémy‐Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Jürgen Behr, Vincent Cottin, Sonye K. Danoff, Ferrán Morell, Kevin Flaherty, Athol U. Wells, Fernando J. Martínez, Arata Azuma, Thomas Bice, Demosthenes Bouros, Kevin M. Brown, Harold R. Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, Gísli Jenkins, Takeshi Johkoh, Ella A. Kazerooni, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar Pipavath, Ivette Buendía-Roldán, Moisés Selman, William D. Travis, Simon Walsh, Kevin C. Wilson - American Journal of Respiratory and Critical Care Medicine 2018 cited by 4,100

  3. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

    Authors: Oliver Distler, Kristin B. Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D. Mayes, Ganesh Raghu, Wiebke Sauter, M Girard, Margarida Alves, Emmanuelle Clerisme-Beaty, Susanne Stowasser, Kay Tetzlaff, Masataka Kuwana, Toby M. Maher - New England Journal of Medicine 2019 cited by 1,613

  4. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline

    Authors: Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A. Cuello‐García, Arata Azuma, Juergen Behr, Jan Brożek, Harold R. Collard, William E. Cunningham, Sakae Homma, Takeshi Johkoh, Fernando J. Martínez, Jeffrey L. Myers, Shandra Protzko, Luca Richeldi, David M. Rind, Moisés Selman, Arthur C. Theodore, Athol U. Wells, Henk C. Hoogsteden, Holger J. Schünemann - American Journal of Respiratory and Critical Care Medicine 2015 cited by 1,930

  5. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

    Authors: Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Heßlinger, Susanne Stowasser, Claudia Valenzuela, Marlies Wijsenbeek, Donald F. Zoz, Florian Voß, Toby M. Maher - New England Journal of Medicine 2022 cited by 217

  6. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis ― Digest Version ―

    Authors: Fumio Terasaki, Arata Azuma, Toshihisa Anzai, Nobukazu Ishizaka, Yoshio Ishida, Mitsuaki Isobe, Takayuki Inomata, Hatsue Ishibashi‐Ueda, Yoshinobu Eishi, Masafumi Kitakaze, Kengo Kusano, Yasushi Sakata, Noriharu Shijubo, Akihito Tsuchida, Hiroyuki Tsutsui, Takatomo Nakajima, Satoshi Nakatani, Taiko Horii, Yoshikazu Yazaki, Etsuro Yamaguchi, Tetsuo Yamaguchi, Tomomi Ide, Hideo Okamura, Yasuchika Kato, Masahiko Goya, Mamoru Sakakibara, Kyoko Soejima, Toshiyuki Nagai, Hiroshi Nakamura, Takashi Noda, Takuya Hasegawa, Hideaki Morita, Tohru Ohe, Yasuki Kihara, Yoshihiko Saito, Yukihiko Sugiyama, Shin-ichiro Morimoto, Akira Yamashina, on behalf of the Japanese Circulation Society Joint Working Group - Circulation Journal 2019 cited by 464

  7. Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline

    Authors: Ganesh Raghu, Sydney B. Montesi, Richard M. Silver, Tanzib Hossain, Madalina Macrea, Derrick Herman, Hayley Barnes, Ayodeji Adegunsoye, Arata Azuma, Leland W.K. Chung, Gregory C. Gardner, Kristin B. Highland, Marie Hudson, Robert J. Kaner, Martin Kolb, Mary Beth Scholand, Virginia Steen, Carey C. Thomson, Elizabeth R. Volkmann, Fredrick M. Wigley, Dee Burlile, Karen Kemper, Shandra L. Knight, Marya Ghazipura - American Journal of Respiratory and Critical Care Medicine 2023 cited by 160

  8. Pirfenidone in idiopathic pulmonary fibrosis

    Authors: H. Taniguchi, Masahito Ebina, Yasuhiro Kondoh, T. Ogura, Arata Azuma, Motomu Suga, Y. Taguchi, Hiroki Takahashi, Kohei Nakata, Akitoshi Sato, M. Takeuchi, Ganesh Raghu, S. Kudoh, T. Nukiwa - European Respiratory Journal 2009 cited by 946

  9. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.

    Authors: Marc A. Judson, Ulrich Costabel, Marjolein Drent, Athol U. Wells, Lisa A. Maier, Laura L. Koth, Hidenobu Shigemitsu, D.A. Culver, Jeffrey M. Gelfand, Dominique Valeyre, Nadera Sweiss, Elliott D. Crouser, Adam S. Morgenthau, Elyse E. Lower, Arata Azuma, Mami Ishihara, Shin‐ichiro Morimoto, Tetsuo Yamaguchi, Noriharu Shijubo, Jan C. Grutters, Misha Rosenbach, Huiping Li, Paola Rottoli, Yoshikazu Inoue, Antje Prasse, Robert P. Baughman, The Wasog Sarcoidosis Organ Assessment Instrument Investigators - 2014 cited by 504

  10. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

    Authors: Kristin B. Highland, Oliver Distler, Masataka Kuwana, Yannick Allanore, Shervin Assassi, Arata Azuma, Arnaud Bourdin, Christopher P Denton, Jörg H W Distler, Anna‐Maria Hoffmann‐Vold, Dinesh Khanna, Maureen D. Mayes, Ganesh Raghu, Madelon C Vonk, Martina Gahlemann, Emmanuelle Clerisme-Beaty, M Girard, Susanne Stowasser, Donald F. Zoz, Toby M. Maher - The Lancet Respiratory Medicine 2021 cited by 212

  11. Consensus statement for the diagnosis and treatment of drug-induced lung injuries

    Authors: Keishi Kubo, Arata Azuma, Minoru Kanazawa, Hideto Kameda, Masahiko Kusumoto, Akihiko Genma, Yasuo Saijo, Fumikazu Sakai, Yukihiko Sugiyama, Koichiro Tatsumi, Makoto Dohi, Hitoshi Tokuda, Shu Hashimoto, Noboru Hattori, Masayuki Hanaoka, Yuh Fukuda - Respiratory Investigation 2013 cited by 279

  12. Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

    Authors: Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi, Atsuhiko Sato, Shoji Kudoh, Ganesh Raghu - American Journal of Respiratory and Critical Care Medicine 2005 cited by 954

  13. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

    Authors: Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida, Matthias Klüglich, Tsuyoshi Fujimoto, Kotaro Okazaki, Yusuke Tadayasu, Wataru Sakamoto, Yukihiko Sugiyama - European Respiratory Journal 2014 cited by 215

  14. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS

    Authors: Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R. Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma - American Journal of Respiratory and Critical Care Medicine 2015 cited by 279

  15. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

    Authors: Toby M. Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna‐Maria Hoffmann‐Vold, Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies Wijsenbeek, Carl Coeck, Christina Schlecker, Florian Voß, Daniel Wachtlin, Fernando J. Martínez - BMJ Open Respiratory Research 2023 cited by 24

  16. Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies

    Authors: Go J. Yoshida, Arata Azuma, Yukiko Miura, Akira Orimo - International Journal of Molecular Sciences 2019 cited by 129

  17. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

    Authors: Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M. Maher, Fernando J. Martínez, Justin M. Oldham, Claudia Valenzuela, Maud Gordat, Yi Liu, Susanne Stowasser, Donald F. Zoz, Marlies Wijsenbeek - BMJ Open Respiratory Research 2023 cited by 37

  18. Epidemiology of sarcoidosis in Japan

    Authors: Tohru Morimoto, Arata Azuma, Shinya Abe, Jiro Usuki, Shoji Kudoh, K Sugisaki, Masaru Oritsu, T. Nukiwa - European Respiratory Journal 2007 cited by 421

  19. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

    Authors: Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M. Maher, Fernando J. Martinez, Justin M. Oldham, Claudia Valenzuela, Emmanuelle Clerisme-Beaty, Maud Gordat, Daniel Wachtlin, Yi Liu, Christina Schlecker, Susanne Stowasser, Donald F. Zoz, Marlies Wijsenbeek - New England Journal of Medicine 2025 cited by 163

  20. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

    Authors: Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C. Magnus Sköld, Sara Tomassetti, Philip Hormel, John L. Stauffer, Indiana Strombom, Klaus-Uwe Kirchgaessler, Toby M. Maher - ERJ Open Research 2018 cited by 119

  21. Exosome-Derived microRNA-22 Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation in Vitro and in Vivo

    Authors: Naoyuki Kuse, Koichiro Kamio, Arata Azuma, Kuniko Matsuda, Minoru Inomata, Jiro Usuki, Akemi Morinaga, Toru Tanaka, Takeru Kashiwada, Kenichiro Atsumi, Hiroki Hayashi, Yoshinobu Saito, Masahiro Seike, Akihiko Gemma - Journal of Nippon Medical School 2019 cited by 74

  22. Japanese guideline for the treatment of idiopathic pulmonary fibrosis

    Authors: Sakae Homma, Masashi Bando, Arata Azuma, Susumu Sakamoto, Keishi Sugino, Yoshiki Ishii, Shinyu Izumi, Naohiko Inase, Yoshikazu Inoue, Masahito Ebina, Takashi Ogura, Kazuma Kishi, Tomoo Kishaba, Takashi Kido, Akihiko Gemma, Yoshihito Goto, Shinichi Sasaki, Takeshi Johkoh, Takafumi Suda, Kazuhisa Takahashi, Hiroki Takahashi, Yoshio Taguchi, Hiroshi Date, Hiroyuki Taniguchi, Takeo Nakayama, Yasuhiko Nishioka, Yoshinori Hasegawa, Noboru Hattori, Junya Fukuoka, Atsushi Miyamoto, Hiroshi Mukae, Akihito Yokoyama, Ichiro Yoshino, Kentaro Watanabe - Respiratory Investigation 2018 cited by 134

  23. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

    Authors: Kimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, Arata Azuma, Yasuhiro Kondoh, Takashi Ogura, Yoshio Taguchi, Masahito Ebina, Hiroki Sakaguchi, Shogo Miyazawa, Moritaka Suga, Yukihiko Sugiyama, Toshihiro Nukiwa, Shoji Kudoh, Hiroki Takahashi - Respiratory Research 2020 cited by 35

  24. Nerandomilast in Patients with Progressive Pulmonary Fibrosis

    Authors: Toby M. Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna‐Maria Hoffmann‐Vold, Michael Kreuter, Justin M. Oldham, Luca Richeldi, Claudia Valenzuela, Marlies Wijsenbeek, Emmanuelle Clerisme-Beaty, Carl Coeck, Heng Gu, Ivana Ritter, Arno Schlosser, Susanne Stowasser, Florian Voß, Gerrit Weimann, Donald F. Zoz, Fernando J. Martínez - New England Journal of Medicine 2025 cited by 139